Should I buy or sell Lyell Immunopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LYEL shares. View LYEL analyst ratings or view top-rated stocks .

What is Lyell Immunopharma's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month price targets for Lyell Immunopharma's shares. Their LYEL share price targets range from $5.00 to $6.00. On average, they expect the company's share price to reach $5.50 in the next year. This suggests a possible upside of 136.1% from the stock's current price. View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts .

How have LYEL shares performed in 2024?

Lyell Immunopharma's stock was trading at $1.94 on January 1st, 2024. Since then, LYEL shares have increased by 20.1% and is now trading at $2.33. View the best growth stocks for 2024 here .

Are investors shorting Lyell Immunopharma?

Lyell Immunopharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 18,100,000 shares, an increase of 74.4% from the March 15th total of 10,380,000 shares. Based on an average trading volume of 964,000 shares, the short-interest ratio is presently 18.8 days. Approximately 15.5% of the shares of the stock are short sold. View Lyell Immunopharma's Short Interest .

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LYEL earnings forecast .

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The business earned $0.01 million during the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative trailing twelve-month return on equity of 32.67%.

What ETFs hold Lyell Immunopharma's stock?

ETFs with the largest weight of Lyell Immunopharma (NASDAQ:LYEL) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) . Hypatia Women CEO ETF (WCEO) .

When did Lyell Immunopharma IPO?

Lyell Immunopharma (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free LYEL Stock Alerts

$2.33

-0.05 (-2.10%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.26
▼
$2.42
50-Day Range: $1.76
▼
$3.07
52-Week Range: $1.32
▼
$3.97

Volume: 906,617 shs
Average Volume: 1.01 million shs
Market Capitalization: $592.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Get Lyell Immunopharma alerts:

Lyell Immunopharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 136.1% Upside
$5.50 Price Target
Short Interest: Bearish
15.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.54
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.81) to ($0.83) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

674th out of 918 stocks

Pharmaceutical Preparations Industry

293rd out of 402 stocks

3.3

Analyst's Opinion

Consensus Rating
Lyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
15.53% of the float of Lyell Immunopharma has been sold short.
Short Interest Ratio / Days to Cover
Lyell Immunopharma has a short interest ratio ("days to cover") of 18.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Lyell Immunopharma has recently increased by 74.37%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lyell Immunopharma does not currently pay a dividend.
Dividend Growth
Lyell Immunopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LYEL.

2.5

News and Social Media Coverage

News Sentiment
Lyell Immunopharma has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Lyell Immunopharma this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for LYEL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
4 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.00% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lyell Immunopharma are expected to decrease in the coming year, from ($0.81) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lyell Immunopharma is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lyell Immunopharma is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lyell Immunopharma has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About Lyell Immunopharma Stock (NASDAQ:LYEL)

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LYEL Stock News Headlines

April 16, 2024 | morningstar.com

Lyell Immunopharma Inc Ordinary Shares LYEL

April 14, 2024 | americanbankingnews.com

Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Up to $2.66

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 12, 2024 | benzinga.com

Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday

April 4, 2024 | finance.yahoo.com

Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting

April 2, 2024 | seekingalpha.com

Biomea Fusion drops as JPMorgan downgrades on data for lead asset

March 20, 2024 | finance.yahoo.com

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

March 17, 2024 | finance.yahoo.com

Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

March 10, 2024 | finanznachrichten.de

Lyell Immunopharma, Inc: Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

March 5, 2024 | globenewswire.com

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

February 28, 2024 | finance.yahoo.com

Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights

February 28, 2024 | globenewswire.com

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

February 26, 2024 | globenewswire.com

Lyell Immunopharma Announces Participation in March Investor Conferences

February 20, 2024 | investing.com

Lyell Immunopharma Inc (LYEL)

January 30, 2024 | benzinga.com

Lyell Immunopharma Stock (NASDAQ:LYEL) Dividends: History, Yield and Dates

January 3, 2024 | finance.yahoo.com

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023 | health.usnews.com

Heather D. Lyell

December 19, 2023 | finance.yahoo.com

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

November 10, 2023 | seekingalpha.com

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

November 10, 2023 | markets.businessinsider.com

Why Lyell Immunopharma Shares Are Rising Today

November 9, 2023 | msn.com

Lyell gets FDA orphan drug designation for melanoma drug candidate

November 9, 2023 | finance.yahoo.com

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

November 8, 2023 | msn.com

Lyell Immunopharma reports Q3 results

November 7, 2023 | finance.yahoo.com

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

October 31, 2023 | finance.yahoo.com

Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

October 9, 2023 | finance.yahoo.com

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 49% stake

See More Headlines

Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LYEL
CUSIP: N/A
CIK: 1806952
Web: www.lyell.com
Phone: 650-695-0677
Fax: N/A
Employees: 224
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $6.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +130.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-234,630,000.00
Net Margins: -180,486.14%
Pretax Margin: -180,486.17%
Return on Equity: -32.67%
Return on Assets: -28.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.07
Quick Ratio: 16.07

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 4,671.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.60 per share
Price / Book: 0.92

Miscellaneous

Outstanding Shares: 254,100,000
Free Float: 193,113,000
Market Cap: $607.30 million
Optionable: Optionable
Beta: -0.56

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Richard D. Klausner M.D. (Age 72)
Founder & Executive Chairman
Comp: $80k
Dr. Lynn Seely M.D. (Age 65)
Ph.D., President, CEO & Director
Comp: $430.69k
Mr. Charles W. Newton (Age 52)
Chief Financial Officer
Comp: $1.72M
Mr. Stephen J. Hill (Age 54)
Chief Operating Officer
Comp: $1.04M
Dr. Gary Lee Ph.D. (Age 47)
Chief Scientific Officer
Comp: $639.91k
Ms. Elizabeth Homans (Age 58)
Consultant
Comp: $1.99M
Prof. Stanley R. Riddell M.D.
Founder & Scientific Advisor
Dr. Crystal L. Mackall M.D. (Age 63)
Founder & Scientific Advisor
Nellie Dillery
Director of Accounting
Ms. Ellen Rose
Senior Vice President of Communications & Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LYEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LYEL shares.
View LYEL analyst ratings or view top-rated stocks.
What is Lyell Immunopharma's stock price target for 2024?: 2 Wall Street research analysts have issued twelve-month price targets for Lyell Immunopharma's shares. Their LYEL share price targets range from $5.00 to $6.00. On average, they expect the company's share price to reach $5.50 in the next year. This suggests a possible upside of 136.1% from the stock's current price.
View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts.
How have LYEL shares performed in 2024?: Lyell Immunopharma's stock was trading at $1.94 on January 1st, 2024. Since then, LYEL shares have increased by 20.1% and is now trading at $2.33.
View the best growth stocks for 2024 here.
Are investors shorting Lyell Immunopharma?: Lyell Immunopharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 18,100,000 shares, an increase of 74.4% from the March 15th total of 10,380,000 shares. Based on an average trading volume of 964,000 shares, the short-interest ratio is presently 18.8 days. Approximately 15.5% of the shares of the stock are short sold.
View Lyell Immunopharma's Short Interest.
When is Lyell Immunopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LYEL earnings forecast.

How were Lyell Immunopharma's earnings last quarter?: Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The business earned $0.01 million during the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative trailing twelve-month return on equity of 32.67%.
What ETFs hold Lyell Immunopharma's stock?: ETFs with the largest weight of Lyell Immunopharma (NASDAQ:LYEL) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Hypatia Women CEO ETF (WCEO).
When did Lyell Immunopharma IPO?: Lyell Immunopharma (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.
How do I buy shares of Lyell Immunopharma?: Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYEL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial